DYADIC INTERNATIONAL INC (DYAI) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$2.05M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$1.90M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$1.93M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$1.73M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$2.05M | (m) | $961.14K | (m) | (m) | -$1.82M* | $984.16K | $332.62K | (m) | $0.00* |
| 2026-03-31 | Reported | (m) | -$1.90M | (m) | $1.11M | (m) | (m) | -$1.96M | $791.84K | $476.07K | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$1.93M | (m) | $1.16M | (m) | (m) | -$1.85M* | $1.02M | $571.87K | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$1.73M | (m) | $966.63K | (m) | (m) | -$130.01K* | $613.59K | $629.38K | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$2.00M | (m) | $393.57K | (m) | (m) | -$1.95M | $297.66K | $494.98K | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$202.61K | (m) | $1.96M | (m) | (m) | -$201.06K* | $395.89K | $460.24K | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$2.04M | (m) | $385.90K | (m) | (m) | -$1.96M* | $301.96K | $515.63K | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$2.13M | (m) | $334.62K | (m) | (m) | -$1.11M | $143.96K | $522.72K | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$1.72M | (m) | $397.06K | (m) | (m) | -$1.96M* | $105.87K | $716.35K | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$2.29M | (m) | $837.16K | (m) | (m) | -$1.65M* | $792.94K | $917.55K | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$2.05M | (m) | $978.05K | (m) | (m) | -$2.19M | $726.92K | $810.57K | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$1.86M | (m) | $879.60K | (m) | (m) | -$1.78M* | $602.85K | $743.59K | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$3.32M | (m) | $658.55K | (m) | (m) | -$1.78M* | $411.11K | $1.83M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$2.74M | (m) | $648.43K | (m) | (m) | -$2.85M | $404.75K | $1.34M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$3.32M | (m) | $692.93K | (m) | (m) | -$4.33M* | $392.54K | $1.90M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$3.87M | (m) | $937.09K | (m) | (m) | $1.90B* | $829.50K | $2.21M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$3.32B | (m) | $460.52M | (m) | (m) | -$1.91B | $390.76M | $1.81B | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$2.58M | (m) | $416.36K | (m) | (m) | -$1.38M* | $266.93K | $986.05K | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$2.80M | (m) | $524.27K | (m) | (m) | -$1.91M* | $624.24K | $1.12M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$2.38M | (m) | $315.37K | (m) | (m) | -$2.00M | $278.18K | $755.45K | (m) | $0.00 |
| 2019-09-30 | Reported | (m) | -$1.94M | (m) | $454.51K | (m) | (m) | -$1.54M* | $384.80K | $841.34K | (m) | $0.00 |
| 2019-06-30 | Reported | (m) | -$2.96M | (m) | $390.87K | (m) | (m) | -$1.43M* | $322.23K | $818.24K | (m) | $0.00 |
| 2019-03-31 | Reported | (m) | -$2.44M | (m) | $402.53K | (m) | (m) | -$1.41M | $327.90K | $692.37K | (m) | $900.00 |
| 2018-09-30 | Reported | (m) | -$1.78M | (m) | $262.96K | (m) | (m) | -$801.34K* | $243.41K | $476.63K | (m) | $0.00 |
| 2018-06-30 | Reported | (m) | -$1.82M | (m) | $161.29K | (m) | (m) | -$1.72M* | $129.12K | $601.20K | (m) | $0.00 |
| 2018-03-31 | Reported | (m) | -$2.23M | (m) | $184.33K | (m) | (m) | -$660.76K | $146.81K | $576.88K | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$7.19M | (m) | $3.09M | (m) | (m) | -$5.70M | $2.32M | $2.15M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$5.90M | (m) | $3.50M | (m) | (m) | -$3.97M | $1.19M | $2.04M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$8.23M | (m) | $2.90M | (m) | (m) | -$6.73M | $1.98M | $3.30M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$10.17M | (m) | $2.93M | (m) | (m) | -$8.08M | $2.12M | $4.50M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$14.73M | (m) | $2.40M | (m) | (m) | -$11.28M | $1.94M | $8.39M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$10.03M | (m) | $1.60M | (m) | (m) | -$6.57M | $1.42M | $3.87M | (m) | $31.32K |
| 2019-12-31 | Reported | (m) | -$9.28M | (m) | $1.68M | (m) | (m) | -$5.78M | $1.46M | $3.09M | (m) | $10.31K |
| 2018-12-31 | Reported | (m) | -$7.59M | (m) | $1.30M | (m) | (m) | -$4.41M | $1.03M | $2.10M | (m) | -$1.01M |
| 2017-12-31 | Reported | (m) | -$7.13M | (m) | $758.42K | (m) | (m) | -$1.69M | $680.20K | $1.77M | (m) | -$66.69K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |